Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COALIZAO ACTION
  NCT04394377		 RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive
    COALIZAO ACTION
          NCT04394377    		 RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID 19 hospitalizedsome concern
    		311/304 inconclusive
      Bousquet OBSanticoagulant, prophylactic doseanticoagulant, curative doseCOVID 19 hospitalizedNA
      		-/- inconclusive
        Bousquet OBSanticoagulant, curative dosecontrolCOVID 19 hospitalizedNA
        		-/- suggested
        • suggested 62 % decrease in deaths
        Bousquet OBSanticoagulant, prophylactic dosecontrolCOVID 19 hospitalizedNA
        		-/- suggested
        • suggested 57 % decrease in deaths
        Paranjpe OBSanticoagulantcontrolCOVID 19 hospitalizedcritical
        		786/1987 no results
          the primary result seems inconclusive (no p value given, but in-hospital mortality for AC was 22.5% with a median survival of 21 days, compared to 22.8% and median survival of 14 days in control group)

          COVID-19 mild to moderate meta-analysis

          ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
                      NCT02735707          		 RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
          		1190/1054 conclusif
          • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
          atypical endpoints without correspondence with those of the others trials
          ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
                      NCT02735707          		 RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
          		1190/1054 conclusif
          • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
          atypical endpoints without correspondence with those of the others trials
          RAPID (Sholzberg)
                      NCT04362085          		 RCTheparin at therapeutic dosestandard of careCOVID-19 mild to moderatesome concern
          		228/237 suggested
          • suggested 78 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias
          • inconclusive 31 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias

          COVID-19 severe or critically meta-analysis

          COVID-PACT RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
          		191/191 suggested
          • suggested 44 % decrease in Major thrombotic events or death (PE) with a moderate degree of certainty due to some concern in risk of bias
          INSPIRATION
                      NCT04486508          		 RCTanticoagulation, intermediate prophylactic dosecontrolCOVID-19 severe or criticallysome concern
          		276/286 inconclusive
          • inconclusive 7 % increase in Thromboembolic events (PE) with a moderate degree of certainty due to some concern in risk of bias
          INSPIRATION
                      NCT04486508          		 RCTanticoagulation, intermediate prophylactic doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
          		276/286 inconclusive
          • inconclusive 7 % increase in Thromboembolic events (PE) with a moderate degree of certainty due to some concern in risk of bias
          REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
                      NCT02735707          		 RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
          		591/616 inconclusive
          • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
          REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
                      NCT02735707          		 RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
          		591/616 inconclusive
          • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
          Tang OBSanticoagulant, prophylactic dosecontrolCOVID-19 severe or criticallyserious
          		99/350 inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

             

            - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons